Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Leuk Lymphoma. 2020 May 2;61(9):2180–2190. doi: 10.1080/10428194.2020.1759051

Table 3:

Treatment regimens and outcomes

Disease ORR (%) CR/CRi for AML (%)
CR/mCR for MDS (%)
Median OS (mos, 95% CI)
AML
 Induction chemotherapy (n=20 pts) 9 (45.0%) 9 (45.0%) 8.8 (1.9–15.5)
 LIT (HMA-based regimens, LDAC) [n=14 pts] 2 (14.3%) 2 (14.3%) 9.4 (1.8–13.6)
MDS
 HMA-based regimens [n=19 pts] 7 (36.8%) 6 (31.6%) 12.1 (5.8-not reached)